Clinical observation of Qiliqiangxin capsule combined with recombinant human brain natriuretic peptide in patients with acute heart failure.
10.3760/cma.j.cn112138-20220420-00291
- Author:
Ming YE
1
;
Xin WANG
2
;
Yue SUN
2
;
Ji HUANG
1
;
Yu Jie ZENG
1
;
Hai GAO
1
Author Information
1. Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing 100029,China.
2. Department of Cardiovascular Medicine, Jilin Provincial People's Hospital, Changchun 130021, China.
- Publication Type:Randomized Controlled Trial
- MeSH:
Humans;
Heart Failure/physiopathology*;
Natriuretic Peptide, Brain/therapeutic use*;
Stroke Volume/physiology*;
Ventricular Function, Left/physiology*;
Cardiotonic Agents/therapeutic use*;
Drugs, Chinese Herbal/therapeutic use*;
Recombinant Proteins/therapeutic use*;
Cardiovascular Agents/therapeutic use*;
Drug Therapy, Combination
- From:
Chinese Journal of Internal Medicine
2023;62(4):422-426
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the clinical effect of Qiliqiangxin capsule combined with recombinant human brain natriuretic peptide in acute left heart failure patients 7 days after onset as well as the effects of plasma MDA and ET-1. Methods: In total, 240 hospitalized patients with acute left heart failure from October 2017 to May 2021 were selected from the Department of Emergency and Critical Care Center of Beijing Anzhen Hospital, Capital Medical University and the Department of Cardiology of the Jilin Provincial People's Hospital. They were randomly divided into routine treatment group and combined treatment group, with 120 cases in each group. The routine treatment group was treated with vasodilation, diuresis, cardiotonic and recombinant human brain natriuretic peptide. The combined treatment group was treated with Qiliqiangxin capsules based on the routine treatment group. One week later, the changes in clinical efficacy, ejection fraction, left ventricular commoid diameter, and plasma BNP, MDA, and ET-1 were compared between the two groups before and after treatment. SPSS 11.5 statistical software was used. The measurement data was expressed in x¯±s, the independent sample t-test was used for comparison between groups, and the paired t-test was used for comparison before and after treatment within groups. Counting data was expressed as case (%), and the rank sum test was used for inter-group comparison. Result: In terms of clinical efficacy, the total effective rate of the combined treatment group was significantly higher than that of the conventional treatment group, and the difference was statistically significant (P<0.05). Compared with the routine treatment group, the left ventricular ejection fraction in the combined treatment group was significantly increased (P<0.05). The levels of plasma BNP, MDA and ET-1 were significantly decreased (P<0.05). Conclusion: Qiliqiangxin capsule combined with rhBNP treatment can effectively improve the clinical symptoms of acute heart failure, as well as reduce the lipid peroxidation product MDA content and endothetin ET-1 level in blood. The clinical application value of the Qiliqiangxin capsule needs to be further confirmed by further trials.
